Source: Virtual Congress 2021 – Biomarkers and risk factors in childhood asthma



Rating:

Share or cite this content

Citations should be made in the following way:
S. Merid (Stockholm, Sweden), S. Björkander (Stockholm, Sweden), D. Brodin (Huddinge, Sweden), J. Brandström (Stockholm, Sweden), F. Fagerström-Billai (Huddinge, Sweden), M. Van Der Heiden (Stockholm, Sweden), J. Konradsen (Stockholm, Sweden), M. Kabesch (Regensburg, Germany), C. Van Drunen (Amsterdam, Netherlands), G. Kornel (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), U. Potocnik (Maribor, Slovenia), S. J H Vijverberg (Amsterdam, Netherlands), A. Nopp (Stockholm, Sweden), C. Nilsson (Stockholm, Sweden), E. Melén (Stockholm, Sweden). Investigation of gene expression in relation to omalizumab treatment and peanut oral immunotherapy. 3070

Member's Comments

No comment yet.

Related content which might interest you: Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005 Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy vs specific immunotherapy allone Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001 Relationship between pre-treatment specific IgE and the response to omalizumab therapy Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 A sputum gene expression signature predicts oral corticosteroid response in asthma Source: Eur Respir J, 49 (6) 1700180; 10.1183/13993003.00180-2017 Year: 2017 Comparative efficacy of different treatment regimens in mild asthmatic patients with hypersensitivity to rye and wheat Source: Eur Respir J 2002; 20: Suppl. 38, 55s Year: 2002 Impact of omalizumab treatment persistence on asthma control Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Allergen specific immunotherapy efficacy in children with pollen-food allergy syndrome and different IgE profiles to recombinant component-resolved allergens. Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Differential expression of mRNA encoding for pro-inflammatory and angiogenic proteins in aspirin-tolerant and -intolerant asthma, following oral provocative aspirin challenge Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Specific immunotherapy efficiency along with the flixothide (fluticosan propionate) therapy for patients suffering from bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways Year: 2003 Specific immunotherapy with high dose grass allergen tablets was safe in grass pollen induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005 Increased sputum FKBP51 gene expression following Azithromycin add-on therapy in asthma Source: International Congress 2018 – New modalities in asthma treatment Year: 2018 Effects of oromucosal immunotherapy (SLIT) in children with respiratory allergy Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation Year: 2012